FeesSafety
Pluang+

Investigation launched into Arbor Realty after Q3 loss and rising nonperforming assets.

Market News
04 Nov 2026, 18:24 WIB
GlobeNewsWire
View Source
Bearish
Investigation launched into Arbor Realty after Q3 loss and rising nonperforming assets.

Holzer & Holzer, LLC is investigating Arbor Realty Trust for potential violations of federal securities laws following the company's Q3 2026 report showing a $85.4 million net loss and a significant rise in nonperforming assets to $1.25 billion. The increase in delinquencies and real estate owned assets was attributed to rising interest rates, which also caused the company's stock price to fall. Investors who suffered losses are encouraged to contact the law firm to discuss legal options. This investigation highlights concerns about Arbor Realty's financial health and compliance.

Arbor Realty Trust's recent financial troubles come as 126 of 142 Financials-sector US stocks on Pluang rose today. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 04, 2026 23:12 WIB: Rocket Companies Inc. Class A Common Stock (RKT) gained 6.88% to USD 14.76 with a typical hold time of 2 days and 93% buy orders; Affirm Holdings Inc (AFRM) rose 6.71% to USD 76.80 with a 21-day hold; and Upstart Holdings Inc (UPST) increased 6.60% to USD 22.78, held typically for 39 days with 100% buy orders.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
35 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
35 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
35 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
35 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
35 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App